Au cours de la tumorigénèse, les cellules tumorales accumulent plusieurs mutations. Chez les modèles animaux comme la drosophile ou la souris, il a été montré que la coopération d’au moins deux altérations génétiques permet de reproduire une croissance néoplasique dans des cellules épithéliales : la sur-activation d’une voie de signalisation comme Ras or Notch, et des mutations altérant l’adhésion cellulaires ou la polarité. Bien que cette coopération soit très décrite, ses mécanismes sous-jacents ne sont que peu étudiés. Deux principaux modèles peuvent être proposés : soit les altérations génétiques fonctionnent indépendamment (modèle additif), ou ils s’influencent l’un l’autre pour faire émerger de nouveaux comportements (modèle synergique). En utilisant un paradigme généré par Notch de croissance hyperplasique et néoplasique dans des disques larvaires d’aile de Drosophila melanogaster, nous cherchons à confirmer l’un de ces deux modèles.En combinant des analyses de RNAseq et de ChIP, nous avons pu identifier des ensembles de gènes directement activés par Notch dans des disques hyperplasiques (Notch activé) et néoplasiques (Notch activé et perte de polarité). Bien que des cibles directes de la voie Notch soient partagées par les deux types de croissances, nos analyses ont montré qu’une grande partie de ces cibles sont spécifiques de chacune des conditions ce qui suggère que l’état polarisé ou non d’une cellule influence le contrôle transcriptionnel de la voie Notch. Enfin en réalisant un screen centré sur les gènes les plus affectés en néoplasie, nous avons identifié un ensemble de gènes qui contrôlent la transition entre l’hyperplasie et la néoplasie. / During tumourigenesis, tumour cells accumulate many mutations. In animal models such as Drosophila or mouse, the cooperation of at least two genetic insults has been shown to recapitulate neoplastic transformation of epithelial cells: an overactive signalling pathway such as Ras or Notch, and mutations affecting cell adhesion or polarity. While this cooperation is well documented, the mechanisms underlying it are still poorly understood. Two main models could be proposed: either the genetic alterations act independently (additive model), or they influence each other to allow the emergence of new behaviours (synergistic model). Using Notch driven paradigms of hyperplastic and neoplastic growth in Drosophila wing discs, we sought to distinguish between these two models.Combining RNAseq and ChIP analysis, we were able to identify the repertoires of genes directly activated by Notch in hyperplastic discs (Notch activation) and in neoplastic discs (Notch activation and polarity loss). While some Notch direct targets are shared between the two types of growth, our analysis revealed that the majority of Notch targets are actually specific to each condition, suggesting that a correct polarity has a major influence on the transcriptional output of the Notch signalling pathway, and strongly supports the synergistic model. Our studies further revealed that histone composition changes and polycomb mark changes are amongst the mechanisms that redirect the Notch pathway. Finally, using a small scale functional screen centred on the most affected genes in neoplasia, we identified a core set of genes controlling the transition from hyperplastic to neoplastic growth.

Abstract Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome characterized by parathyroid, gastroenteropancreatic and pituitary neuroendocrine tumours. In Northern Finland, two founder mutations of the MEN1 gene (1466del12, 1657insC) accounting for the majority of the MEN1 cases, have common ancestors born in the 18th and 19th centuries, respectively. Three small clusters of familial pituitary adenoma have also been detected, two of which could be linked by genealogy to a common ancestral couple born in the 18th century. Clinical evaluation of 82 MEN1 mutation carriers showed that age was a risk factor for most of the MEN1-related manifestations. In the whole group, nonfunctional pancreatic tumour (NFPT) was more common in the frameshift/nonsense mutation carriers (odds ratio 3.26; 95% confidence interval 1.27–8.33, P = 0.014), whereas gastrinoma was more common in the in-frame/missense mutation carriers (OR 6.77, CI 1.31–35.0, P = 0.022). In the founder mutation carriers, the 1657insC mutation predicted the risk for NFPT (OR 3.56, CI 1.29–9.83, P = 0.015), while the 1466del12 mutation was associated with the risk for gastrinoma (OR 15.1, CI 1.73–131.9, P = 0.014). The mean ages at death of the 32 obligatory MEN1 founder mutation carriers born between 1728 and 1929 were compared to those of the 29 spouses and sex-matched life expectancy estimates derived from Finnish national statistics. The ages at death of the mutation carrier males (61.1 ± 12.0 years) and females (67.2 ± 10.7 years) did not differ from the control groups. PAP (pituitary adenoma predisposition) locus was mapped in the chromosome region 11q12–11q13 by whole-genome single-nucleotide polymorphism genotyping. Combining the linkage and the gene expression array data, AIP (aryl hydrocarbon receptor interacting protein) was chosen for sequencing. The nonsense mutation Q14X was identified in the affected (acromegaly, gigantism, prolactinoma) family members and in four other patients. Loss of heterozygosity was detected in pituitary adenomas of AIP mutation carriers. Mutation analysis of MEN1, HRPT2 (hyperparathyroidism 2), CASR (calcium-sensing receptor), CDKN1B (cyclin-dependent kinase inhibitor 1B) and AIP genes was performed in primary hyperparathyroidism patients with features of inherited predisposition. One out of 29 patients was found to have the 1466del12 mutation, while no mutations were detected in other genes.

Vulval intraepithelial neoplasia (VIN) is a distressing, premalignant condition, frequently associated with type HPV16 infection, with increasing incidence in younger women. Traditional surgical treatment is sub optimal. Several different clinical studies influencing local and/or systemic immunity to HPV have been reported. Imiquimod, an immune response modifier, can stimulate local innate immunity and also drive an adaptive immune response. Therapeutic HPV vaccines are designed to generate cell-mediated immunity against HPV infected cells. The rationale of this study was that local imiquimod treatment, in addition to having a direct effect on VIN could also provide an immunological platform for the therapeutic HPV vaccination to achieve an enhanced and durable response. In this phase II trial, we used a combination of imiquimod and vaccination with TA-CIN (HPV16 E6E7L2 fusion protein). Women with biopsy proven high-grade VIN were recruited. Imiquimod treatment for 8 weeks was followed by three i.m. injections of TA-CIN. The objectives were to measure lesion size, histology, lesion HPV status, symptoms, immune responses before and after treatment as well as safety, toxicity, and tolerability. Lymphoproliferation to HPV antigens was used to analyse immunity to HPV before and after treatment. Local immune factors (CD4, CD8 and T regulatory cells) were assessed by immunofluorescence. 74, 85 and 79% of women had a ≥50% reduction in the size of lesion and 32, 58 and 63% had regression of VIN on histology at weeks 10, 20 and 52 respectively. At baseline, 79% had moderate to severe symptoms compared to 21% at week 52(P=0.01). Of the women who showed histological responses at week 52, 5/10 also cleared their HPV 16 infection. Follow-up for an average of 15 months showed 84% of patients with a ≥50% reduction in lesion size. Treatment was well tolerated. A significant post vaccination increase in proliferation to TA-CIN and its components was associated with histological responders (P=0.008) but not the non-responders (P=0.7). In the group as a whole, significant increases in the number of CD4, CD8 and T regulatory cells (Treg) were evident by week 20 compared to baseline (P=0.03, P=0.01, P= 0.04 respectively); At week 20, the increased CD4 and CD8 density was significantly associated only with the histological responders (P=0.03; P= 0.03) while increased Treg density was associated with only non-responders (P=0.05). Intralesional Treg density was significantly higher in non-responders compared to responders pre and post treatment (P=0.01, 0.05 respectively). This study demonstrated that imiquimod followed by vaccination achieved histological clearance of VIN at 52 weeks in almost 60%. Higher pre-existing and post-treatment levels of Treg cells were associated with a lack of treatment response. Lymphoproliferation of PBMC established that the vaccination was immunogenic and HPV 16 antigen specific. Importantly, these systemic immune responses to HPV 16 antigens were significantly associated with treatment responders.

As anormalidades hematológicas de origem paraneoplásica são identificadas em diversos tipos de neoplasias que acometem cães e gatos. Nas neoplasias mamárias em cadelas, já foram identificadas anormalidades relacionadas com a coagulação, onde verificou-se que a coagulação intravascular disseminada (CID) clínica e subclínica pode estar presente em 83% das cadelas com carcinoma mamário. Na medicina humana, é dada relevância à investigação de tais alterações uma vez que são fatores indicadores de prognóstico do câncer. Enquanto isso, na medicina veterinária, são escassos os estudos que relacionam as alterações hematológicas com o tipo tumoral, estadiamento e determinação de prognóstico. O objetivo do presente estudo foi realizar a avaliação hematológica, bioquímica e da hemostasia de cadelas acometidas por neoplasia mamária para identificar a alteração mais frequente, além de relacionar as anormalidades com o estadiamento tumoral. Para isso, foram utilizadas 25 cadelas atendidas pelo Grupo de Estudos em Oncologia em pequenos animais (ONCOVET) do Hospital de Clínicas Veterinárias da UFRGS (HCV-UFRGS) durante o período de 4 meses. Foi realizado coleta de sangue para hemograma, contagem de plaquetas, bioquímica sérica (albumina, ALT, cálcio, creatinina, FA, glicose, ureia) e teste de coagulação que constou de TP (tempo de protrombina), TTPa (tempo de tromboplastina parcial ativada), TT (tempo de trombina), fibrinogênio e mensuração do dímero-D. O estadiamento tumoral foi obtido através do exame físico e do resultado da biopsia das mamas. As anormalidades encontradas incluíram anemia, leucocitose neutrofílica, monocitose, eosinofilia, trombocitose, hipoalbuminemia, hipocalcemia, hipoglicemia e diminuição dos níveis de ureia sanguínea. Entretanto, essas alterações não foram relacionadas diretamente com a progressão tumoral, uma vez que não houve diferença entre os grupos avaliados. Apenas as variáveis RDW e ALT apresentaram relação significativa entre os grupos, contudo, sem relevância clínica. No teste de coagulação, houve diferença significativa entre os grupos apenas no TT e fibrinogênio, que foi relacionado com o estadiamento tumoral. / Hematological abnormalities of paraneoplastic origin are identified in several types of cancers that affect dogs and cats. In dogs with mammary neoplasms, abnormalities associated with coagulation have been identified, and verified that disseminated intravascular coagulation (DIC) clinical and subclinical may be present in 83% of dogs with mammary carcinoma. In human medicine, research in this field has been relevant since those factors are indicators of cancer prognosis. Meanwhile, in veterinary medicine, there are few studies that relate hematological changes with tumor type, staging and determination of prognosis. The aim of this study was to evaluate the hematological, biochemical and hemostathic abnormalities in bitches affected by mammary cancer to identify the most frequent alteration and associate with tumor staging. For this, 25 bitches attended by the Oncology Study Group in small animals (ONCOVET) of the Veterinary Hospital of UFRGS (HCV-UFRGS) for the period of 4 months were used. Blood collection for complete blood count, platelet count, serum biochemistry (albumin, ALT, calcium, creatinine, ALP, glucose, urea) and coagulation test that consisted of PT (prothrombin time), aPTT (activated partial thromboplastin time), TT (thrombin time), fibrinogen and D-dimer measurement were performed. Tumor staging was obtained by physical examination and the results of the biopsy of the breast. The abnormalities found included anemia, neutrophilic leukocytosis, monocytosis, eosinophilia, thrombocytosis, hypoalbuminemia, hypocalcemia, hypoglycemia and decreased levels of urea. However, these changes were not associated directly with tumor progression, since there was no difference among the groups. Only the RDW and ALT variables was associated significantly between the groups, however, with no clinical relevance. In the coagulation test, there was significant difference between the groups only in TT and fibrinogen, which was associated with tumor staging.

Orientador: Cesar Cabello dos Santos / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-04T02:24:06Z (GMT). No. of bitstreams: 1 Feijo_LuizFernandoAndrade_M.pdf: 3050164 bytes, checksum: 672560c57474869fce1041591b88e14b (MD5) Previous issue date: 2005 / Resumo: Objetivo: Avaliar as taxas de recidiva local após o tratamento cirúrgico conservador de câncer de mama em mulheres submetidas à radioterapia complementar sem reforço. Pacientes e métodos: Foi realizado um estudo de coorte reconstituído com 128 pacientes portadoras de câncer de mama estádios I e 11,que foram tratadas com cirurgia conservadora e radioterapia sem reforço, no período de janeiro de 1989 a dezembrode 1996, no Setor de Mastologia do Centro de Atenção Integral à Saúde da Mulher (CAISM) da Universidade Estadualde Campinas (UNICAMP).A cirurgia da mama foi a quadrantectomiacom axilectomia,seguida de radioterapiacom 25 frações diárias de 2Gy ou 1,8Gy, cinco dias por semana. As pacientes receberam dose total de 50 ou 45Gy, respectivamente. Foi considerada recidiva local a presença de carcinoma (invasivo ou ductal in situ), confirmado através de exame anátomo-patológico, na mama tratada em qualquer momento do período de seguimento. As pacientes foram estudadas segundo os seguintes critérios: faixa etária, tamanho do tumor, presença de gânglios linfáticos axilares comprometidos e intervalo entre a data da cirurgia e a data do início da radioterapia. A análise estatística foi realizada utilizando Curvas de Kaplan Meyer para apresentar as taxas de recidivas locais e os testes de Log Rank, Wilcoxon e razão de risco para avaliar a relação entre os valores de recidiva local e as variáveis: faixa etária, tamanho do tumor, gânglios linfáticos comprometidos e intervalo entre a data da cirurgia e a data do início da radioterapia. Foi também realizada uma análise multivariada para avalia a independênciae a associação entre as variáveis estudadas e a recidiva local. Resultados: A taxa de recidiva local na população geral foi de 28% em 12 anos de seguimento. As pacientes com idade abaixo de 35 anos apresentaram risco de recidiva local três vezes maior do que as com idade acima de 35. Esses valores encontraram-seno limite da significância (p=0,05); (HR=3,0; 95%IC=1,0 - 9,0).Os tumores com tamanho maior de dois centímetros apresentaram risco de recidiva local três vezes maior do que os tumores menores. Esses valores também se encontraram no limite da significância (p=0,05); (HR=3,0; 95%IC=1,0 - 9,0).As taxas de recidivas locais não se associaram ao estado dos gânglios linfáticos axilares (p=0,09); (HR=1,9; 95%IC=0,8-4,9),assim como não se associaram ao intervalo entre a data da cirurgia e a data do início da radioterapia (p=0,5); (HR=0,9; 95%IC=0,3-2,8).Segundo a análise multivariada,a idade abaixo de 35 anos foi a que apresentou a maior associação às recidivas locais (HR=5,0; 95%IC=1,6-18), seguida dos tumores maiores de dois centímetros (HR= 4,0 - IC= 1,2 - 14). Conclusão:As pacientes tratadas de forma conservadora por câncer de mama e submetidas à radioterapia complementar com dose de 45 ou 50GY sem reforço apresentaram 28% de recidivas locais após 12 anos. Essa taxa foi mais elevada do que as observadasem outros estudos que utilizaram radioterapia com reforço.As com idade abaixo de 35 anos, bem como as portadoras de tumores maiores de dois centímetros, associaram-se a um maior risco de recidivas locais. Esses dados sugerem que essa forma de radioterapia seja insuficiente para o tratamento local dessas mulheres, principalmente nos casos de pacientes com idade inferior a 35 anos ou com tumores maiores de dois centímetros / Abstract: Purpose: To evaluate local recurrence rates after breast-conserving surgery for breast cancer treatment in women undergoing adjuvant radiotherapy without a boost. Patients and methods: A retrospective cohort study was conducted on 128 patients diagnosed with stages I and 11breast cancer, who were treated with conservative surgery and radiotherapy without a boost dose in the Division of Senology at the Women's Integral Health Care Center (CAISM) of the Campinas State University (Unicamp) from January 1989 to December 1996. The type of breast surgery was quadrantectomy with axillary Iymph node dissection, followed by radiotherapy delivered in 25 daily fractions of 2 Gy or 1.8 Gy, tive days a week. The patients received a total radiation dose of 50 or 45 Gy, respectively. Local recurrence was defined as the presence of carcinoma (invasive or ductal in situ) in the treated breast, confirmed by histopathologic exam, at any given time during the follow-up period. The patients were studied according to the following criteria: age range, tumor size, presence of involved axillary Iymph nodes and the interval between the date of surgery and the date when radiotherapy began. Statistical analysis was performed using Kaplan Meyer curves to show local recurrence rates. The log-rank test, the Wilcoxon test and risk ratio were used to evaluate the relationship between local recurrence values and variables, e.g. age range, tumor size, Iymph node involvement and the interval between date of surgery and date when radiotherapy began. Multivariate analysis was also performed to evaluate independence and the association between the variables studied and local recurrence. Results: The local recurrence rate was 28% in the general population at twelve years of follow-up. Patients under 35 years had three times more risk of developing local recurrence than those older than 35 years. These values were found within the significance limit (p=0.05); (HR=3.0; 95%CI=1.0 - 9.0). Women with tumors larger than 2 centimeters had three times more risk of developing local recurrence than those with smaller tumors. These values were also found within the significance limit (p=0.05);(HR=3.0; 95%CI=1.0 - 9.0). Local recurrence rates were neither associated with axillary Iymph node status (p=0.09); (HR=1.9; 95%CI=0.8-4.9), nor with the interval between the date of surgery and the date when radiotherapy began (p=0.5); (HR=0.9; 95%CI=0.3- 2.8). According to multivariate analysis, age under 35 years was most strongly associated with local recurrences (HR=5.0; 95%CI=1.6-18), followed by tumors larger than 2 centimeters (HR= 4.0; 95%CI= 1.2 - 14). Conclusion: Patients treated conservatively for breast cancer and undergoing adjuvant radiotherapy in doses of 45 or 50 Gy without a boost had local recurrence rates of 28% afier 12 years. This rate was higher than those observed in other studies using radiotherapy with a boost. Age under 35 years and tumors larger than 2 centimeters were associated with a higher risk of local recurrences. Our data suggest that this type of radiotherapy was insufficient for the local treatment of these women, especially patients under 35 years of age or those with tumors larger than two centimete / Mestrado / Tocoginecologia / Tocoginecologia

Orientador: Rosemeri de Oliveira Vasconcelos / Resumo: A glândula mamária é o segundo sítio mais comum de desenvolvimento tumoral em cadelas. Uma das formas de estadiamento destes tumores é avaliar a presença ou ausência de metástase à distância, inclusive na medula óssea. Este achado, na Medicina, associa-se a baixa sobrevida de mulheres com tumores mamários, porém na Medicina Veterinária esse estadiamento clínico é mais utilizado para pacientes com linfomas e mastocitomas. Estudos que utilizem a biópsia de medula óssea como método de pesquisa de estadiamento em tumores mamários são escassos. Desta forma o presente estudo teve como objetivo avaliar lesões mamárias e a medula óssea de 36 cadelas, buscando-se células tumorais disseminadas ou focos metastáticos. Para isso realizou-se a análise histopatológica dos tumores de mama, linfonodos e medula óssea dessas cadelas, corados com Hematoxilina e Eosina. Na medula óssea também foram utilizadas a coloração com Tricrômio de Masson, para avaliação de fibrose medular, e a imunohistoquímica, para a pesquisa de micrometástase. O carcinoma em tumor misto grau I fora o mais observado (18,08%), não havendo diferença estatística com relação ao tamanho tumoral e a presença de metástase em linfonodos. Na medula óssea de uma cadela com carcinossarcoma (4,35%) houve marcação citoplasmática de uma provável célula tumoral disseminada, de origem epitelial, com o anticorpo citoqueratina-19 pela imunohistoquímica. Nenhuma das cadelas que apresentou diminuição da celularidade ou fibrose medular (Tric... (Resumo completo, clicar acesso eletrônico abaixo) / Mestre

付記する学位プログラム名: 充実した健康長寿社会を築く総合医療開発リーダー育成プログラム / 京都大学 / 0048 / 新制・課程博士 / 博士(医科学) / 甲第22747号 / 医科博第116号 / 新制||医科||8(附属図書館) / 京都大学大学院医学研究科医科学専攻 / (主査)教授 長船 健二, 教授 武藤 学, 教授 小川 誠司 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 新制・課程博士 / 博士(医学) / 甲第23080号 / 医博第4707号 / 新制||医||1049(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 萩原 正敏, 教授 伊藤 貴浩, 教授 稲垣 暢也 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第19567号 / 医博第4074号 / 新制||医||1013(附属図書館) / 32603 / 京都大学大学院医学研究科医学専攻 / (主査)教授 武田 俊一, 教授 小川 誠司, 教授 野田 亮 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

The azanucleosides decitabine and azacytidine are used widely in the treatment of myeloid neoplasia and increasingly in the context of combination therapies. Although they were long regarded as being largely interchangeable in their function as hypomethylating agents, the azanucleosides actually have different mechanisms of action; decitabine interferes primarily with the methylation of DNA and azacytidine with that of RNA. Here, we examine the role of DNA methylation in the lineage commitment of stem cells during normal hematopoiesis and consider how mutations in epigenetic regulators such as DNMT3A and TET2 can lead to clonal expansion and subsequent neoplastic progression. We also consider why the efficacy of azanucleoside treatment is not limited to neoplasias carrying mutations in epigenetic regulators. Finally, we summarise recent data describing a role for azacytidine-sensitive RNA methylation in lineage commitment and in the cellular response to stress. By summarising and interpreting evidence for azanucleoside involvement in a range of cellular processes, our review is intended to illustrate the need to consider multiple modes of action in the design and stratification of future combination therapies.